These results suggested that antagomiR‐29b can effectively prevent the progression of CAVD by possibly promoting TGF‐β3 through repressing the Wnt3/β‐catenin/Smad3 axis, which may serve as a potential target for treatment of CAVD. Here, WNT3 is linked to congenital bilateral aplasia of vas deferens from CFTR mutation.